Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Dec 9, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has filed an Abbreviated New Drug Application for Clobetasol Propionate Topical Spray, 0.05%, a generic form of Clobex® Spray....
-
Dec 7, 2009Gluten-free labeling program an industry first for over-the-counter pharmaceuticals
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced it will implement a labeling program to help consumers more clearly identify more than 200 of the company's over-the-counter store-brand...
-
Nov 19, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Sidoti Emerging Growth Conference on Friday, November 20, at 3:15 p.m....
-
Nov 9, 2009In the news release, Perrigo Company to Present at the Credit Suisse 18th Annual Health Care Conference, issued 09-Nov-2009 by Perrigo Company over PR Newswire, we are advised by the company that in the first paragraph, the conference date and time should
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Credit Suisse 18th Annual Health Care Conference on Wednesday, November...
-
Nov 9, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Credit Suisse 18th Annual Health Care Conference on Wednesday, November...
-
Nov 2, 2009
-- Fiscal first quarter revenue from continuing operations increased $72 million, or 16%, to $528 million -- Fiscal first quarter GAAP income from continuing operations increased 59% to $61...
-
Nov 2, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has signed a definitive agreement to sell its Israel Consumer Products business along with the related production assets in...
-
Oct 29, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.0625 per share, payable on December 15, 2009 to shareholders of record on...
-
Oct 19, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its first quarter fiscal 2010 on Monday, November 2, 2009 at approximately 8:00 a.m. (ET). The...
-
Oct 19, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that the Hatch-Waxman litigation relating to Duac® Gel (clindamycin phosphate (1%) and benzoyl peroxide (5%) gel) filed by the Stiefel...
-
Oct 13, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has filed an Abbreviated New Drug Application for over-the-counter (OTC) Minoxidil topical aerosol foam, 5%, a generic form of...
-
Oct 6, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for...
-
Sep 21, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) will hold its Investor Day from 8:30 a.m. to approximately 12:00 p.m. EDT on September 29, at the NASDAQ MarketSite located at 4 Times Square in New...
-
Sep 21, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has purchased the ANDA for clindamycin phosphate (1%) and benzoyl peroxide (5%) gel from KV Pharmaceutical for $14 million in...
-
Aug 18, 2009- Full-year revenue from continuing operations increased $277 million, or 16 percent, to a record $2 billion - Adjusted income from continuing operations for the full year increased 13 percent to $175 million, or $1.87 per share - GAAP income from continu
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its fourth quarter and full year ended June 27, 2009. Perrigo's Chairman and CEO Joseph C. Papa commented, "Our sales topped...
-
Aug 13, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.055 per share, payable on September 15, 2009 to shareholders of record on...
-
Aug 4, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its fiscal year 2009 on Tuesday, August 18, 2009 at approximately 8:00 a.m. (ET). The Company...
-
Aug 3, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its partner Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) (previously Barr Laboratories Inc.) has received final approval from...
-
Jul 13, 2009
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market over-the-counter coated nicotine polacrilex...
-
Jun 24, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its partner Synthon Pharmaceuticals, Inc. has filed an Abbreviated New Drug Application (ANDA) for Levocetirizine solution...
-
May 7, 2009
-- Fiscal third quarter revenue from continuing operations increased $25 million, or 5%, to $506 million as compared to $481 million this quarter a year ago -- Fiscal third quarter earnings from...
-
May 6, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.055 per share, payable on June 16, 2009 to shareholders of record on May...
-
Mar 24, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration to market Sulfacetamide Sodium Topical Suspension, 10%...
-
Mar 17, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its partner Cobrek Pharmaceuticals, Inc. has filed an Abbreviated New Drug Application (ANDA) for Clindamycin Phosphate Foam 1%, a...
-
Feb 20, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that has begun shipping over-the-counter (OTC) Ibuprofen and Diphenhydramine Citrate Tablets, 200/38 mg. The product will be marketed...